Pharmacologic management of neovascular age-related macular degeneration: Systematic review of economic evidence and primary economic evaluation

Canadian Journal of Ophthalmology

Volumn 45, Issue 3, 2010, Pages 223-230

  Hodge, William ^a   Brown, Allan ^b   Kymes, Steve ^c   Cruess, Alan ^d   Blackhouse, Gord ^e   Hopkins, Robert ^e   McGahan, Lynda ^b   Sharma, Sanjay ^f   Pan, Irene ^a   Blair, Jason ^g   Vollman, David ^c   Morrison, Andra ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH   (Canada)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DALHOUSIE UNIVERSITY   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Age related macular degeneration; Cost effectiveness; Pharmacologic treatment; Quality adjusted life year; Systematic review

Indexed keywords

ANECORTAVE; BEVACIZUMAB; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE; VERTEPORFIN; MONOCLONAL ANTIBODY;

BIOSIS; CANADA; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; EMBASE; HEALTH CARE SYSTEM; HIDDEN MARKOV MODEL; HUMAN; LOW LEVEL LASER THERAPY; MEDLINE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; SIMULATION; SYSTEMATIC REVIEW; VISUAL ACUITY; CHOROIDAL NEOVASCULARIZATION; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; PROBABILITY; PUBLIC HEALTH; WET MACULAR DEGENERATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CANADA; CHOROIDAL NEOVASCULARIZATION; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; NATIONAL HEALTH PROGRAMS; QUALITY-ADJUSTED LIFE YEARS; WET MACULAR DEGENERATION;

EID: 77953310762     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i10-047     Document Type: Review

References (29)

1. Buhrmann R, Hodge W, Gold D. Forecasting the vision loss epidemic in Canada current and projected estimates of age-related eye disease: interim summary tables prepared for the National Coalition on Vision Health 2006.
2. Drugs & health products: notice of compliance. Ottawa, Ont.: Health Canada; 2000. Available at: http://205.193.93.51/NocWeb/viewnoce.jsp?noc5cngj. Accessed January 10, 2008.
3. Notice of decision for Macugen. Ottawa, Ont.: Therapeutic Products Directorate, Health Canada; June 2, 2005. Available at: http://www.hc-sc.gc.ca/ dhp-mps/alt-formats/hpfb-dgpsa/pdf/prodpharma/nd-ad-2005-macugen-094022-e.pdf. Accessed September 15, 2005.
4. Drummond MF, Jefferson TO, BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;13:275-83. Available at: http://www.bmj.com/cgi/content/full/313/7052/ 275. Accessed February 19, 2007.
5. Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration-a value-based reappraisal with 5-year data. Am J Ophthalmol 2005;140:679-687
6. Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol 2001;16:218-222
7. Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol 2004;88:982-987 (Pubitemid 39013134)
8. Larouche K. Photodynamic therapy for the treatment of exudative age-related macular degeneration (ARMD) with subfoveal neovascularization. Montréal: Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS); 2004. Available at: http://www.aetmis.gouv.qc.ca/site/275.447.0.0.1.0.phtml. Accessed February 28, 2007.
9. Meads C. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2003;7:v-vi, 1-98. Available at: http://www.ncchta.org/fullmono/mon709.pdf. Accessed February 28, 2007.
10. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001;108:2051-2059 (Pubitemid 33032778)
11. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: theUKcase. Br J Ophthalmol 2004;88:1107-1112 (Pubitemid 39141365)
12. Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK. Pharmacoeconomics 2007;25:863-879 (Pubitemid 47481636)
13. Raftery J, Jones J, Clegg A, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007;91:1244-1246 (Pubitemid 47344908)
14. Sharma S, Bakal J, Sharma SM, Covert D, Shah GK. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value. Can J Ophthalmol 2005;40:369-377 (Pubitemid 40942263)
15. Javitt JC, Zlateva GP, Earnshaw SR, et al. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health 2008;11:563-574
16. Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther 2007;29:2096-2106
17. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006;24:1043-1053 (Pubitemid 44683362)
18. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York, N.Y.: Oxford University Press; 1997.
19. Markovitz JH, Roubin GS, Parks JM, Bittner V. Platelet activation and restenosis after coronary stenting: flow cytometric detection of wound-induced platelet activation. Coron Artery Dis 1996;7:657-665 (Pubitemid 26397181)
20. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444 (Pubitemid 44511558)
21. Rosenfeld P, Brown D, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431 (Pubitemid 44511557)
22. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999;117:1329-1345
23. Sharma S, Brown GC, Brown MM, et al. Converting visual acuity to utilities. Can J Ophthalmol 2000;35:267-272
24. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd ed. Ottawa, Ont.: The Agency; 2006. Available at: http://www.cadth.ca/media/pdf/186- EconomicGuidelines-e.pdf. Accessed March 12, 2007.
25. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-787
26. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase-1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569-4578
27. Michels S, Rosenfeld P, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047 (Pubitemid 40797459)
28. Moshfeghi A, Rosenfeld P, Puliafito C, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113:2002.e1-12
29. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-637